PitchSend

Investor Presentaiton

Financials Market Capitalisation Rs. 2,140 billion / US$ 33 billion SUN PHARMA (All Figures in Rs. Mn) FY11 YOY FY12 YOY FY13 YOY FY14 YOY FY15* P&L Summary Net Sales 57,229 43% 80,057 40% 112,389 40% 160,044 42% 272,865 Gross Profit 42,577 46% 63,644 49% 91,592 44% 132,250 44% 205,473 EBITDA 19,518 43% 32,507 67% 49,063 51% 71,141 45% 78,166 Net Profit 18,161 34% 26,567 46% 29,830 12% 31,415 5% 45,394 Net Profit (Adjusted) 18,161 34% 26,567 46% 35,666# 34% 56,589 # 59% 47,771# R&D Spend 3,313 26% 4,449 34% 7,042 58% 10,418 48% 19,550 BS Summary Mar'11 YoY Mar'12 Shareholders Funds 94,833 Loan Funds 3,651 Net Fixed Assets 27,568 Investments 22,298 21% 122,358 113% 2,650 64% 32,742 -30% 22,129 YoY Mar'13 29% 149,897 -27% 1,982 19% 50,771 -1% YoY Mar'14 YOY Mar'15* 23% 185,250 24% 255,897 -25% 24,890 75,963 55% 58,242 15% 110,201 24,116 9% 27,860 16% 27,163 Cash and Bank Balances 22,046 333% 33,672 53% 40,587 21% 75,902 87% 109,980 Inventory 14,895 39% 20,870 40% 25,778 24% 31,230 21% 56,680 Sundry Debtors 11,049 -6% 20,787 88% Sundry Creditors 6,454 102% 9,927 24,122 54% 10,580 16% 22,004 7% -9% 53,123 13,283 26% 31,538 All figures from FY11 to FY14 exclude Ranbaxy aqcuisition which is effective from 01 April 2014 * FY15 numbers include the impact of Ranbaxy merger © Sun Pharmaceutical Industries Limited. All Rights Reserved. Exchange Rate: For Market Capitalisation US$1 = Rs 65.22 (As on 31 Oct 2015) # Adjusted for Rs 5.83 bn provision related to generic Protonix settlement for the year 2012-13 and adjusted for Rs 25.17 bn provision related to generic Protonix settlement for the year 2013-14 and adjusted for Rs 2.4 bn for settlement provision for Texas Medicaid Program litigation for 2014-15 45

View entire presentation